Vaccine supply, demand, and policy: A primer

Journal of the American Pharmacists Association

Volumn 49, Issue 4, 2009, Pages

  Muzumdar, Jagannath M ^a   Cline, Richard R ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Drug policy; Medication demand; Medication supply; Vaccines

Indexed keywords

VACCINE;

DRUG COST; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG LEGISLATION; ECONOMICS; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; GOVERNMENT REGULATION; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HUMAN; LEGAL ASPECT; MEDICARE; PUBLIC OPINION; REVIEW; SAFETY; UNITED STATES;

CONSUMER PRODUCT SAFETY; DRUG COSTS; DRUG DISCOVERY; DRUG INDUSTRY; GOVERNMENT REGULATION; HEALTH POLICY; HEALTH SERVICES ACCESSIBILITY; HUMANS; LEGISLATION, DRUG; MARKETING OF HEALTH SERVICES; MEDICARE PART D; PUBLIC OPINION; RESEARCH SUPPORT AS TOPIC; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; VACCINES;

EID: 67651049202     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1331/JAPhA.2009.09007     Document Type: Article

References (80)

1. Orenstein WA, Douglas RG, Rodewald LE, Hinman AR. Immunizations in the United States: success, structure, and stress. Health Aff. 2005;24:599-610.
2. Salinsky E, Werble C. The vaccine industry: does it need a shot in the arm? National Health Policy Forum. Washington, DC: George Washington University; 2006:1-34.
3. Arthur A. Vaccines: the controversial story of medicine's greatest lifesaver. Part II. New York, W.W. Norton & Company; 2007:12, 27.
4. Ulmer JB, Valley U, Rappuoli R. Vaccine manufacturing: challenges and solutions. Nat Biotechnol. 2006; 24:1377-83.
5. Zhou F, Santoli J, Messonnier ML, et al. Economic evaluation of the 7-vaccine routine childhood immunization schedule in the United States, 2001. Arch Pediatr Adolesc Med. 2005;159:1136-44.
6. Salo H, Kilpi T, Sintonen H, et al. Cost-effectiveness of influenza vaccination of healthy children. Vaccine. 2006;24:4934-41.
7. Paul Y. Herd immunity and herd protection. Vaccine. 2004;22:301-2.
8. Ritvo P, Wilson K, Willms D, Upshur R. Vaccines in the public eye. Nat Med. 2005;11(4 suppl):S20-4.
9. Bloom D, Canning D, Malaney P. Demographic change and economic growth in East Asia. Popul Dev Rev. 2000;26:257-90.
10. Bloom D, Canning D. The health and wealth of nations. Science. 2000;(Feb 18):1207-9.
11. Andre FE, Booy R, Bock HL, et al. Vaccination greatly reduces disease, disability, death and inequity worldwide. Bull World Health Organ. 2008;86:140-6.
12. Nordhaus W. The health of nations: the contribution of improved health to living standards. In: Murphy KH, Topel RH, Eds. Measuring the gains from medical research: an economic approach. Chicago: University of Chicago Press; 2003.
13. Centers for Disease Control and Prevention. Impact of vaccines universally recommended for children: United States, 1990-1998. MMWR Morb Mortal Wkly Rep. 1999;48(12):243-8.
14. Bridges CB, Thompson WW, Meltzer MI, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized control trial. JAMA. 2000;284:908-13.
15. Demicheli V, Rivetti D, Deeks JJ, Jefferson TO. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2004;CD001269.
16. Iglehart J. Financing vaccines: in search of solutions that work. Health Aff. 2005;24:594-5.
17. Calfee JE, Gottlieb S. Putting markets to work in vaccine manufacturing. Accessed at www.aei.org/publications/pubID.21659/pub-detail.asp, October 22, 2007.
18. Offit P. Why are pharmaceutical companies gradually abandoning vaccines? Health Aff. 2005;24:622-30.
19. Centers for Disease Control and Prevention. Vaccines & immunizations: 2002 immunization news. Accessed at www.cdc.gov/vaccines/news/news-pubs/ news2002.htm, December 04, 2007.
20. National Vaccine Advisory Committee. Strengthening the supply of routinely recommended vaccines in the United States: recommendations from the National Vaccine Advisory Committee. JAMA. 2003;290:3122-8.
21. American Academy of Pediatrics. Red Book online: special alert: Hib shortage. Accessed at http://aapredbook.aappublications.org/news, January 5, 2008.
22. Hinman AR, Orenstein WA, Santoli JM, et al. Vaccine shortages: history, impact, and prospects for the future. Annu Rev Public Health. 2006;27:235-59.
23. Reuters Health Information. Tropical Dengue fever may threaten U.S.: report. Accessed at www.reuters.com/article/bondsNews/idUSN0847856420080108, January 10, 2008.
24. Thwing J, Skarbinski J, Newman RD, et al. Malaria surveillance: United States, 2005. MMWR Surveill Summ. 2007;56(6):23-40.
25. Centers for Disease Control and Prevention. Measles: United States, January 1-April 25, 2008. Accessed at www.cdc.gov/mmwr/preview/mmwrhtml/ mm5718a5.htm, June 8, 2008.
26. Donnelly CA, Fischer MC, Fraser C, et al. Epidemiological and genetic analysis of severe acute respiratory syndrome. Lancet Infect Dis. 2004;4:672-83.
27. Food and Drug Administration. Just the facts: vaccines provide effective protection and FDA makes sure they are safe. Accessed at www.fda.gov/opacom/ factsheets/justthefacts/19vaccine.html, November 22, 2007.
28. Thaul S. CRS report for Congress: vaccine policy issues. Accessed at www.fas.org/sgp/crs/misc/RL31793.pdf, November 30, 2007.
29. Glass RI, Kilgore PE, Holman RC, et al. The epidemiology of rotavirus diarrhea in the United States: surveillance and estimates of disease burden. J Infect Dis. 1996;174(1 suppl):S5-11.
30. Food and Drug Administration, Center for Biologics Evaluation and Research. Vaccine product approval process: 2002. Accessed at www.fda.gov/Cber/vaccine/vacappr.htm, November 12, 2007.
31. Plotkin S, Orenstein W, Offit P. Vaccines. 5th ed. Toronto, Canada: Elsevier; 2008:37, 39.
32. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003;22:151-85.
33. Sloan F, Berman S, Rosenbaum S, et al. The fragility of the US vaccine supply. N Engl J Med. 2004;351:2443-7.
34. Dooren JC. Merck recalls childhood vaccine. Accessed at http://online.wsj.com/article/SB119749483569624501.html, December 20, 2007.
35. Institute of Medicine. Financing vaccines in the 21st century. 1st ed., chapters 1 and 3. Washington, DC: National Academies Press; 2003.
36. Mercer Management Consulting. Lessons learned: new procurement strategies for vaccines: final report to the GAVI Board. New York: Mercer Management Consulting; 2002.
37. Thompson WW, Price C, Goodson B, et al. Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years. N Engl J Med. 2007;357:1281-92.
38. Tozzi AE, Bisiacchi P, Tarantino V, et al. Neuropsychological performance 10 years after immunization in infancy with thimerosal-containing vaccines. Pediatrics. 2009;123:475-82.
39. Offit P. Autism's false prophets: bad science, risky medicine, and the search for a cure. 1st ed. New York: Columbia University Press; 2008.
40. Centers for Disease Control and Prevention. Withdrawal of rotavirus vaccine recommendation. Accessed at www.cdc.gov/mmwr/preview/mmwrhtml/mm4843a5. htm, November 23, 2007.
41. Hinman AR, Orenstein WA, Rodewald L. Financing immunizations in the United States. Clin Infect Dis. 2004;38:1440-6.
42. Hinman AR, Orenstein WA, Santoli JM, et al. Vaccine shortages: history, impact, and prospects for the future. Annu Rev Public Health. 2006;27:235-59.
43. Centers for Disease Control and Prevention. National, state, and local area vaccination coverage among children aged 19-35 months: United States, 2007. MMWR Morb Mortal Wkly Rep. 2008;57:961-6.
44. Corrigan J. New data show unacceptably low adult immunization rates and that adults unaware of infectious disease threat. Accessed at www.reuters.com/article/pressRelease/idUS181452+23-Jan-2008+PRN20080123, May 30, 2009.
45. King DA, Peckham C, Waage JK. Epidemiology: infectious diseases: preparing for the future. Science. 2006;313:1392-3.
46. Lee GM, Santoli J, Hannan C, et al. Gaps in vaccine financing for underinsured children in the United States. JAMA. 2007;298:638-43.
47. Coleman M, Fontanesi J, Meltzer MI, et al. Estimating medical practice expenses from administering adult influenza vaccinations. Vaccine. 2005;23:915-23.
48. Freed GL, Cowan AE, Clark SJ. Primary care physician perspectives on reimbursement for childhood immunizations. Pediatrics. 2008;122:2008-33.
49. Benin AL, Wisler-Scher DJ, Colson E, et al. Qualitative analysis of mothers' decision-making about vaccines for infants: the importance of trust. Pediatrics. 2006;117:1532-41.
50. Kennedy AM, Brown CJ, Gust DA. Vaccine beliefs of parents who oppose compulsory vaccination. Public Health Rep. 2005;120:252-8.
51. Gust DA, Darling N, Kennedy A, Schwartz B. Parents with doubts about vaccines: which vaccines and reasons why. Pediatrics. 2008;122:718-25.
52. Boardman AE, Greenberg DH, Vining AR, Weimer DL. Cost-benefit analysis: concepts and practice. Upper Saddle River, NJ: Prentice Hall; 1996(appendix 3B):99-110.
53. Gottron F. CRS report for Congress: RS21507 Project Bioshield. Accessed at www.au.af.mil/au/awc/awcgate/crs/rs21507.pdf, December 27, 2007.
54. Food and Drug Administration. Project Bioshield: protecting Americans from terrorism. Accessed at www.fda.gov/fdac/features/2004/604-terror.html, August 2, 2008.
55. U.S. Department of Health and Human Services. Pandemic and All-Hazard Preparedness Act. Accessed at www.hhs.gov/aspr/opsp/pahpa/index.html, May 29, 2009.
56. Food and Drug Administration. Guidance for industry, fast track drug development programs: designation, development, and application review. Accessed at www.fda.gov/cber/gdlns/fsttrk.pdf, November 25, 2007.
57. Hendrickson D. Biovest moves to Fast Track with cancer vaccine. Accessed at www.masshightech.com/stories/2006/05/22/story11-Biovest-moves-to-Fast-Track- with-cancer-vaccine.html, August 2, 2008.
58. Frederick. FDA grants "fast track" designation for the development of OncoVAX. July 2006. Accessed at www.vaccinogeninc.com/news-0706. cfm August 08, 2008.
59. U.S. Government Printing Office. 21 CFR 601 subpart E: accelerated approval of biological products for serious or life-threatening illnesses. Accessed at http://edocket.access.gpo.gov/cfr-2008/aprqtr/pdf/21cfr601.40.pdf, November 24, 2007.
60. Food and Drug Administration. CFR - Code of Federal Regulations Title 21. Accessed at www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm? CFRPart=601&showFR=1&subpartNode=21:7.0.1.1.2.5, November 24, 2007.
61. Gelb L. FDA approves new influenza vaccine for upcoming flu season. Accessed at www.fda.gov/bbs/topics/news/2005/NEW01227.html, July 18, 2008.
62. Food and Drug Administration. Fast track, priority review and accelerated approval. Accessed at www.accessdata.fda.gov/scripts/cder/onctools/Accel.cfm, December 7, 2007.
63. Food and Drug Administration. FDA licenses new vaccine for prevention of cervical cancer and other diseases in females caused by human papillomavirus. Accessed at www.fda.gov/bbs/topics/news/2006/new01385.html, July 31, 2008.
64. U.S. Department of Health and Human Services, Health Resources and Services Administration. National Vaccine Injury Compensation Program (VICP). Accessed at www.hrsa.gov/vaccinecompensation, November 26, 2007.
65. Cohen H. CRS report for Congress: RL31649, Homeland Security Act of 2002: tort liability provisions. Accessed at www.policyarchive.org/bitstream/handle/ 10207/1557/RL31649-20050923.pdf?sequence=1, November 30, 2007.
66. Thaul S. CRS report for Congress: RL31960, smallpox vaccine injury compensation. Accessed at http://biotech.law.lsu.edu/blaw/bt/smallpox/Congress/ RL31960.pdf, November 30, 2007.
67. U.S. Department of Health and Human Services. Public Readiness and Emergency Preparedness Act questions and answers. Accessed at www.hhs.gov/disasters/emergency/manmadedisasters/bioterorism/ medication-vaccine-qa.html, March 12, 2009.
68. GAVI Alliance. Accessed at www.gavialliance.org, January 10, 2008.
69. Batson A. The problems and promise of vaccine markets in developing countries. Health Aff. 2005;24:690-3.
70. U.S. Department of Health and Human Services. CDC efforts in implementing a smallpox vaccination program. Accessed at www.hhs.gov/asl/testify/t030129. html, January 10, 2008.
71. Gillis J. U.S. builds stockpile of vaccine for flu pandemic. Accessed at www.washingtonpost.com/wp-dyn/content/article/2005/11/29/AR2005112901849.html, June 23, 2008.
72. Timiraos N. Why a market-driven vaccine plan faces big obstacles. Accessed at http://online.wsj.com/public/article-print/SB119906129300958545. html, January 10, 2008.
73. Maclnnis L. Vaccine bonds provide model for other aid projects. Accessed at www.medscape.com/viewarticle/573432, April 30, 2008.
74. GAVI Alliance. GAVI Alliance announces dramatic funding boost for Hib vaccine. Accessed at www.gavialliance.org/media-centre/press-releases/2007-11- 29-en-pr-hib-boost.php, August 11, 2008.
75. Lindley MC, Orenstein WA, Shen AK, et al. Assuring vaccination of children and adolescents without financial barriers: recommendations from the National Vaccine Advisory Committee (NVAC). Washington, DC: U.S. Department of Health and Human Services; 2009.
76. Atkinson WL, Hadler SC, Redd SB, Orenstein WA. Measles surveillance: United States, 1991. MMWR CDC Surveill Summ. 1992;41:1-12.
77. Centers for Disease Control and Prevention. Vaccines & immunizations: Vaccines for Children Program (VFC). Accessed at www.cdc.gov/vaccines/programs/ vfc, June 12, 2008.
78. Centers for Disease Control and Prevention. Childhood vaccine supply policy 2007. Accessed at www.cdc.gov/vaccines/programs/vfc/projects/data/vacc- supply-public-2007.htm, May 29, 2009.
79. Freed GL, Clark SJ, Pathman DE, et al. Impact of North Carolina's universal vaccine purchase program by children insurance status. Arch Pediatr Adolesc Med. 1999;153:748-54.
80. Centers for Medicare and Medicaid Services. Adult immunization. Accessed at www.cms.hhs.gov/adultImmunizations, June 25, 2008.